Navigate through 4 recent analyst ratings for Legend Biotech LEGN within the last quarter:

Discover the 12-month price targets set by 4 analysts for Legend Biotech in the last quarter. The average target is $82.75, with a high estimate of $93.00 and a low estimate of $65.00.

Discover a summary of 4 analysts' ratings for Legend Biotech over the last 3 months. Increased bullish ratings indicate a positive sentiment, while increased bearish ratings signal a negative outlook.

A decline of 5.61% from the prior average price target is evident in the current average.

Analyzing Analyst Ratings: A Detailed Breakdown

Navigate through the viewpoints of financial experts and analysts with an in-depth analysis of their recent evaluations for Legend Biotech. The Ratings Table below offers a comprehensive overview of the decisions made by influential analysts, their current ratings, and price targets. Gaining insights into the perceptions of these experts towards the company can unveil valuable perspectives on possible market trends and investor sentiment.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Legend Biotech. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Legend Biotech compared to the broader market.
• Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Legend Biotech's stock. This comparison reveals trends in analysts' expectations over time.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Legend Biotech's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Legend Biotech analyst ratings.

All You Need to Know About Legend Biotech

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America.

Legend Biotech: Delving into Financials

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: Legend Biotech displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 250.91%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: Legend Biotech's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -64.79%, the company may face hurdles in effective cost management.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -4.53%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.3%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: Legend Biotech's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.24.

What Are Analyst Ratings?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.